MDV: Multidose vial; NA: Not available ... Practices related to predrawing the vaccine into unmarked plastic syringes were observed that could impact patient safety and reduce vaccine potency.

The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults ...

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

for the world’s first and only chikungunya vaccine, Ixchiq. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in ...

Valneva has received Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

We observed tasks in the vaccine preparation process, from the time of removal of the vial or the syringe package from the refrigerator until the time it was ready to be administered to a patient.